/
Discussion Outline Cells of the Immune System Discussion Outline Cells of the Immune System

Discussion Outline Cells of the Immune System - PowerPoint Presentation

lois-ondreau
lois-ondreau . @lois-ondreau
Follow
351 views
Uploaded On 2018-11-13

Discussion Outline Cells of the Immune System - PPT Presentation

Innate Immunity Receptors on T and B Cells Are Specific for Each Antigen Innate and Adaptive Immune Systems Antigen Presentation Adaptive Immunity Function of the Immune System Tumor Escape Mechanisms ID: 728870

references cont system immune cont references immune system antigen patients cells ipilimumab tumor abbreviations cancer studies response antigens nivolumab

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "Discussion Outline Cells of the Immune S..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1
Slide2
Slide3
Slide4

Discussion OutlineSlide5

Cells of the Immune SystemSlide6

Innate ImmunitySlide7

Receptors on T and B Cells Are Specific for Each AntigenSlide8

Innate and Adaptive Immune SystemsSlide9

Antigen PresentationSlide10

Adaptive ImmunitySlide11

Function of the Immune SystemSlide12

Tumor Escape MechanismsSlide13

Risk for Malignancies Is Higher in Immunosuppressed Patients With Organ Transplants Compared With in Healthy Individuals*Slide14

Cancer and ImmunoeditingSlide15

Antigen Presentation and T-Cell PrimingSlide16

Reasons for Failed Vaccine StudiesSlide17

Tumor AntigensSlide18

Dual Role of the Immune System in CancerSlide19

Chimeric Antigen-Receptor T Cells for LymphomaSlide20

Multiple Costimulatory and Inhibitory Interactions Regulate T-Cell ResponsesSlide21

CTLA-4: Negatively Modulates the Immune ResponseSlide22

Phase 3 Trial of Ipilimumab in MelanomaSlide23

Progression-Free Survival in Patients Receiving Ipilimumab for Lung CancerSlide24

Immune Checkpoints Regulate the Immune SystemSlide25

Phase 1 Study: Activity of NivolumabSlide26

Targeted Agents Against Immune Checkpoint PathwaysSlide27

Antibodies to Tumor-Expressing AntigensSlide28

Measuring Response With Immune TherapiesSlide29

Future ObjectivesSlide30

Nivolumab + Ipilimumab in Patients With Advanced MelanomaSlide31

Combination Studies of Checkpoint InhibitorsSlide32

ConclusionsSlide33

AbbreviationsSlide34

Abbreviations (cont)Slide35

Abbreviations (cont)Slide36

ReferencesSlide37

References (cont)Slide38

References (cont)Slide39

References (cont)Slide40

References (cont)Slide41

References (cont)Slide42

References (cont)Slide43

References (cont)Slide44

References (cont)Slide45

References (cont)Slide46

References (cont)Slide47

References (cont)